PubMed:19891556 / 0-310 JSONTXT

{"project":"LitCoin-entities","denotations":[{"id":"6773","span":{"begin":0,"end":11},"obj":"ChemicalEntity"},{"id":"6774","span":{"begin":123,"end":134},"obj":"ChemicalEntity"},{"id":"6775","span":{"begin":171,"end":194},"obj":"DiseaseOrPhenotypicFeature"},{"id":"6776","span":{"begin":195,"end":203},"obj":"OrganismTaxon"},{"id":"6777","span":{"begin":283,"end":291},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"6773","obj":"MESH:D000077144"},{"id":"A2","pred":"db_id","subj":"6774","obj":"MESH:D000077144"},{"id":"A3","pred":"db_id","subj":"6775","obj":"MESH:D003324"},{"id":"A4","pred":"db_id","subj":"6776","obj":"NCBITaxon:9606"},{"id":"A5","pred":"db_id","subj":"6777","obj":"NCBITaxon:9606"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.\nAntiplatelet therapy with clopidogrel is the current standard of care for coronary artery disease patients undergoing a percutaneous coronary intervention. However, approximately 25% of patients experience a subth"}

{"project":"LitCoin-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":96},"obj":"Sentence"},{"id":"T2","span":{"begin":97,"end":252},"obj":"Sentence"}],"text":"Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.\nAntiplatelet therapy with clopidogrel is the current standard of care for coronary artery disease patients undergoing a percutaneous coronary intervention. However, approximately 25% of patients experience a subth"}

{"project":"LitCoin_Mondo","denotations":[{"id":"T1","span":{"begin":171,"end":194},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0005010"}],"text":"Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.\nAntiplatelet therapy with clopidogrel is the current standard of care for coronary artery disease patients undergoing a percutaneous coronary intervention. However, approximately 25% of patients experience a subth"}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T1","span":{"begin":162,"end":166},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":262,"end":275},"obj":"GeneOrGeneProduct"}],"text":"Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.\nAntiplatelet therapy with clopidogrel is the current standard of care for coronary artery disease patients undergoing a percutaneous coronary intervention. However, approximately 25% of patients experience a subth"}

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T1","span":{"begin":171,"end":194},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"originalLabel","subj":"T1","obj":"D003324"}],"text":"Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.\nAntiplatelet therapy with clopidogrel is the current standard of care for coronary artery disease patients undergoing a percutaneous coronary intervention. However, approximately 25% of patients experience a subth"}

{"project":"LitCoin_Mondo_095","denotations":[{"id":"T1","span":{"begin":171,"end":194},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0005010"}],"text":"Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.\nAntiplatelet therapy with clopidogrel is the current standard of care for coronary artery disease patients undergoing a percutaneous coronary intervention. However, approximately 25% of patients experience a subth"}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T1","span":{"begin":171,"end":194},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"ID:","subj":"T1","obj":"D003324"}],"text":"Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.\nAntiplatelet therapy with clopidogrel is the current standard of care for coronary artery disease patients undergoing a percutaneous coronary intervention. However, approximately 25% of patients experience a subth"}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T1","span":{"begin":171,"end":194},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"#label","subj":"T1","obj":"D003324"}],"text":"Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.\nAntiplatelet therapy with clopidogrel is the current standard of care for coronary artery disease patients undergoing a percutaneous coronary intervention. However, approximately 25% of patients experience a subth"}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T1","span":{"begin":0,"end":11},"obj":"ChemicalEntity"},{"id":"T4","span":{"begin":123,"end":134},"obj":"ChemicalEntity"}],"attributes":[{"id":"A1","pred":"ID:","subj":"T1","obj":"D000077144"},{"id":"A2","pred":"ID:","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_37941"},{"id":"A3","pred":"ID:","subj":"T1","obj":"ChemicalEntity"},{"id":"A4","pred":"ID:","subj":"T4","obj":"D000077144"},{"id":"A5","pred":"ID:","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_37941"},{"id":"A6","pred":"ID:","subj":"T4","obj":"ChemicalEntity"}],"text":"Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.\nAntiplatelet therapy with clopidogrel is the current standard of care for coronary artery disease patients undergoing a percutaneous coronary intervention. However, approximately 25% of patients experience a subth"}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T1","span":{"begin":195,"end":203},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":283,"end":291},"obj":"OrganismTaxon"}],"text":"Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.\nAntiplatelet therapy with clopidogrel is the current standard of care for coronary artery disease patients undergoing a percutaneous coronary intervention. However, approximately 25% of patients experience a subth"}

{"project":"LitCoin-training-merged","denotations":[{"id":"T4","span":{"begin":123,"end":134},"obj":"ChemicalEntity"},{"id":"T1","span":{"begin":0,"end":11},"obj":"ChemicalEntity"},{"id":"T27020","span":{"begin":171,"end":194},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T78738","span":{"begin":283,"end":291},"obj":"OrganismTaxon"},{"id":"T48935","span":{"begin":195,"end":203},"obj":"OrganismTaxon"}],"attributes":[{"id":"A6","pred":"ID:","subj":"T4","obj":"ChemicalEntity"},{"id":"A5","pred":"ID:","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_37941"},{"id":"A4","pred":"ID:","subj":"T4","obj":"D000077144"},{"id":"A3","pred":"ID:","subj":"T1","obj":"ChemicalEntity"},{"id":"A2","pred":"ID:","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_37941"},{"id":"A1","pred":"ID:","subj":"T1","obj":"D000077144"},{"id":"A42748","pred":"#label","subj":"T27020","obj":"D003324"}],"text":"Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.\nAntiplatelet therapy with clopidogrel is the current standard of care for coronary artery disease patients undergoing a percutaneous coronary intervention. However, approximately 25% of patients experience a subth"}